FMP
Oct 8, 2021 5:06 PM - Davit Kirakosyan
Allogene Therapeutics, Inc. (NASDAQ:ALLO) shares dropped more than 45% on Friday following the U.S. Food and Drug Administration’s (FDA) halt on the company’s AlloCAR T clinical trials after the detection of AlloCAR cells with chromosomal abnormality in a single patient treated with ALLO-501A.
Rafael Amado, Executive Vice President of Research and Development and Chief Medical Officer of Allogene, said that they will work closely with the FDA to determine the next steps for advancing ALLO-501A. As the company investigates the issue, the analysts at Oppenheimer think that there will be delayed development timelines for key programs including ALLO-501A and ALLO-715, estimating the holds to range from 3 to 6 months.
Following this announcement, the analysts lowered their price target on the company’s shares to $40 from $44, while maintaining their outperform rating.
Sep 11, 2023 1:38 PM - Rajnish Katharotiya
Price to Earnings is one of the key metrics use to value companies using multiples. The P/E ratio and other multiples are relative valuation metrics and they cannot be looked at in isolation. One of the problems with the P/E metric is the fact that if we are in the peak of a business cycle, earni...
Sep 11, 2023 1:49 PM - Rajnish Katharotiya
Price-to-Earnings ratio is a relative valuation tool. It is used by investors to find great companies at low prices. In this post, we will build a Python script to calculate Price Earnings Ratio for comparable companies. Photo by Skitterphoto on Pexels Price Earnings Ratio and Comparable Compa...
Oct 17, 2023 3:09 PM - Davit Kirakosyan
Shares of VMware (NYSE:VMW) witnessed a sharp drop of 12% intra-day today due to rising concerns about China's review of the company's significant sale deal to Broadcom. Consequently, Broadcom's shares also saw a dip of around 4%. Even though there aren’t any apparent problems with the proposed solu...